Month: September 2021

Victory Square Portfolio Company, Fantasy 360 Technologies Inc., Signs Binding Letter of Intent to Acquire Synthesis VR Inc., A leading Location-based Virtual Reality Content Store & Technology Engine Powering 300 Global Locations

Written by Customer Service on September 20, 2021. Posted in Mergers And Acquisitions.

/NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES./This acquisition provides Fantasy 360 with leading software and distribution capabilities that will establish its accelerated growth in the fast growing $140 Billion VR/AR market (see PwC market analysis here)The Synthesis VR software engine provides everything the modern VR arcade and Family Entertainment Center needs to power its VR experiences, a vital component of many locations internationallySynthesis VR is the only platform that supports Free Roam, Room-Scale, and Android-based tetherless Virtual Reality entertainment, a Gold Standard for VR arcade operatorsSynthesis VR provides over 325 Games and other experiences available through its extensive store catalogueSynthesis VR supports approximately 300 entertainment centre clients...

Giyani Announces Update on Exploration Activities at its Manganese Projects, Botswana

Written by Customer Service on September 20, 2021. Posted in Public Companies.

Not for distribution to U.S. newswire services or for dissemination in the United States TORONTO, Sept. 20, 2021 (GLOBE NEWSWIRE) — Giyani Metals Corp. (TSXV:EMM, GR:A2DUU8) (“Giyani” or the “Company“), developer of the K.Hill manganese oxide project (“K.Hill Project”) in Botswana, is pleased to provide an update on its exploration programs at the southern extension of its K.Hill Project (“K.Hill Extension”), the Otse manganese prospect (“Otse”) and Lobatse manganese prospect (“Lobatse”). HighlightsCommencement of a diamond drilling (“DD”) program to verify the characteristics of the newly discovered mineralized horizon at K.Hill Extension, announced on August 19, 2021. Geological database from previous reverse circulation (“RC”) drilling shared with SRK Consulting (“SRK”) to commence block modelling for...

Verizon Chairman & CEO to speak at Goldman Sachs conference September 21

Written by Customer Service on September 20, 2021. Posted in Public Companies.

NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) — Hans Vestberg, Chairman and CEO for Verizon, is scheduled to speak at the virtual Goldman Sachs 30th Annual Communacopia Conference on Tuesday, September 21, at 8:00 a.m. ET. His remarks will be webcast, with access instructions available on Verizon’s Investor Relations website, www.verizon.com/about/investors/. Verizon Communications Inc. (NYSE, Nasdaq: VZ) was formed on June 30, 2000 and is one of the world’s leading providers of technology, communications, information and entertainment products and services. Headquartered in New York City and with a presence around the world, Verizon generated revenues of $128.3 billion in 2020. The company offers data, video and voice services and solutions on its award-winning networks and platforms, delivering on customers’ demand for mobility,...

OSE Immunotherapeutics Presented Positive Final Results of Tedopi® Phase 3 Clinical Trial in Secondary Resistant Non-Small Cell Lung Cancer Patients at the European Society for Medical Oncology (ESMO) Virtual Congress 2021

Written by Customer Service on September 20, 2021. Posted in Public Companies.

Results show statistical improvement in overall survival, favorable benefit/risk ratio and better quality of life in NSCLC patients after secondary resistance to checkpoint inhibitors NANTES, France, Sept. 20, 2021 (GLOBE NEWSWIRE) — OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that the positive final results of its Phase 3 trial of neoepitope-based cancer vaccine Tedopi®, called Atalante 1, in HLA-A2 positive patients with advanced non-small cell lung cancer (NSCLC) after immune checkpoint inhibitor (PD-1/PD-L1) failure, were presented in a late-breaking oral presentation(1) at the European Society for Medical Oncology (ESMO) Virtual Congress being held on September 16 – 21, 2021. Pr. Benjamin Besse, Director of Clinical Research at Gustave Roussy (Villejuif, France), and Principal Investigator of the...

Fantasy 360 Signs Binding Letter of Intent to Acquire Synthesis VR Inc., A leading Location-based Virtual Reality Content Store & Technology Engine Powering 300 Global Locations

Written by Customer Service on September 20, 2021. Posted in Mergers And Acquisitions.

This acquisition provides Fantasy 360 with leading software and distribution capabilities that will establish its accelerated growth in the fast growing $140 Billion VR/AR market (see PWC market analysis here)The Synthesis VR software engine provides everything the modern VR arcade and Family Entertainment Center needs to power its VR experiences, a vital component of many locations internationallySynthesis VR is the only platform that supports Free Roam, Room-Scale, and Android-based tetherless Virtual Reality entertainment, a Gold Standard for VR arcade operatorsSynthesis VR provides over 325 Games and other experiences available through it’s extensive content catalogueSynthesis VR supports approximately 300 entertainment centre clients with locations across North America, Europe, India, South East Asia and Latin AmericaSynthesis...

Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster and Immunogenicity Enhancer

Written by Customer Service on September 20, 2021. Posted in Public Companies.

GRT-R910, a self-amplifying mRNA (SAM) SARS-CoV-2 vaccine, delivers antigens from both the spike protein and highly conserved non-spike proteins for broad protection across variants Induction of CD8+ T cells in addition to neutralizing antibody responses offers potential for robust and persistent immunity, especially in at-risk populations (eg older individuals and those who are immunocompromised) Initial Phase 1 data from this study are expected in the first Quarter 2022 EMERYVILLE, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that the first volunteer has been dosed in a Phase 1 trial evaluating the ability of GRT-R910, a self-amplifying mRNA (SAM) second generation SARS-CoV-2...

Radisson Collection Hotel, Palazzo Touring Club Milan opens its doors in the heart of Milan

Written by Customer Service on September 20, 2021. Posted in Public Companies.

Radisson Collection Hotel, Palazzo Touring Club Milan guest room designRadisson Collection Hotel, Palazzo Touring Club Milan guest room designRadisson Collection Hotel, Palazzo Touring Club Milan restaurantRadisson Collection Hotel, Palazzo Touring Club Milan restaurantRadisson Collection Hotel, Palazzo Touring Club Milan suiteRadisson Collection Hotel, Palazzo Touring Club Milan suiteRadisson Collection Hotel, Palazzo Touring Club Milan exteriorRadisson Collection Hotel, Palazzo Touring Club Milan exteriorRadisson Collection Hotel, Palazzo Touring Club Milan lobby areaRadisson Collection Hotel, Palazzo Touring Club Milan lobby areaRadisson Collection Hotel, Palazzo Touring Club Milan opens its doors in the heart of Milan Set in an iconic building at the...

Matinas BioPharma Announces Accomplished Biotechnology Executive and Drug Developer Kathryn Penkus Corzo as Nominee to the Board of Directors

Written by Customer Service on September 20, 2021. Posted in Public Companies.

– Ms. Corzo brings a 25+ year successful track record in biopharma, excelling in oncology drug development with Takeda, Sanofi Genzyme, and Eli Lilly – BEDMINSTER, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform delivery technology, today announced the nomination of Kathryn Penkus Corzo to stand for election to the Company’s Board of Directors at its 2021 Annual Meeting of Stockholders, scheduled for November 1, 2021. Ms. Corzo is currently partner at Takeda Ventures, Inc. and previously Head of Oncology Cell Therapy Development at Takeda Pharmaceuticals, a global, values-based, R&D-driven biopharmaceutical...

Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference

Written by Customer Service on September 20, 2021. Posted in Public Companies.

DEVON, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will participate in a fireside chat during the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 11:20 a.m. ET. Investors interested in arranging a virtual meeting with the Company’s management during the conference should contact the Cantor conference coordinator. A webcast of the fireside chat will be available under the Events & Webcasts tab of the Investors section of the Zynerba website at www.zynerba.com. An archived replay will be available on the Company’s website following the...

Algernon Pharmaceuticals Announces Plans for a Phase 2 Ifenprodil Chronic Cough Study in the U.S.

Written by Customer Service on September 20, 2021. Posted in Public Companies.

VANCOUVER, British Columbia, Sept. 20, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF) (FRANKFURT: AGW) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it plans to file a pre-IND (Investigational New Drug) meeting request with the U.S. Food and Drug Administration (U.S. FDA) for an NP-120 (Ifenprodil) Phase 2 chronic cough study. Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B). The decision to expand its Ifenprodil research program was based on positive trending interim data received by the Company from the chronic cough part of its 20-patient Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough study being conducted in Australia and New Zealand. The interim...

Month: September 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals